| Primary |
| Prophylaxis |
28.6% |
| Pulmonary Hypertension |
22.8% |
| Acute Respiratory Distress Syndrome |
6.3% |
| Persistent Foetal Circulation |
5.3% |
| Hypoxia |
4.9% |
| Product Used For Unknown Indication |
4.9% |
| Oxygen Saturation Decreased |
4.4% |
| Pulmonary Arterial Hypertension |
3.4% |
| Pulmonary Arterial Pressure Increased |
2.9% |
| Respiratory Failure |
2.4% |
| Sickle Cell Anaemia |
2.4% |
| Neonatal Respiratory Distress Syndrome |
1.9% |
| Bronchopulmonary Dysplasia |
1.5% |
| Medical Device Implantation |
1.5% |
| Premature Baby |
1.5% |
| Ventricular Assist Device Insertion |
1.5% |
| Acute Respiratory Failure |
1.0% |
| Congenital Diaphragmatic Hernia |
1.0% |
| Lung Disorder |
1.0% |
| Myocardial Infarction |
1.0% |
|
| Oxygen Saturation Decreased |
21.8% |
| Device Failure |
11.3% |
| Death |
7.5% |
| Cardio-respiratory Arrest |
6.8% |
| Patent Ductus Arteriosus |
6.8% |
| Device Malfunction |
4.5% |
| General Physical Health Deterioration |
4.5% |
| Intraventricular Haemorrhage Neonatal |
3.8% |
| Pulmonary Haemorrhage |
3.8% |
| Cardiac Arrest |
3.0% |
| Cognitive Disorder |
3.0% |
| Drug Ineffective |
3.0% |
| Off Label Use |
3.0% |
| Respiratory Failure |
3.0% |
| Sepsis Neonatal |
3.0% |
| Hypotension |
2.3% |
| Neonatal Disorder |
2.3% |
| Neonatal Hypotension |
2.3% |
| No Therapeutic Response |
2.3% |
| Pneumothorax |
2.3% |
|
| Secondary |
| Pulmonary Hypertension |
36.0% |
| Prophylaxis |
10.0% |
| Hypoxia |
8.0% |
| Oxygen Saturation Decreased |
8.0% |
| Product Used For Unknown Indication |
6.0% |
| Acute Respiratory Distress Syndrome |
4.0% |
| Acute Respiratory Failure |
4.0% |
| Neonatal Aspiration |
4.0% |
| Neonatal Respiratory Distress Syndrome |
4.0% |
| Oxygen Supplementation |
4.0% |
| Persistent Foetal Circulation |
4.0% |
| Bronchopulmonary Dysplasia |
2.0% |
| Lung Disorder |
2.0% |
| Pulmonary Arterial Pressure Increased |
2.0% |
| Venous Oxygen Saturation |
2.0% |
|
| Oxygen Saturation Decreased |
35.0% |
| Device Failure |
17.5% |
| Medical Device Complication |
5.0% |
| Sepsis |
5.0% |
| Cardio-respiratory Arrest |
2.5% |
| Central Venous Pressure Increased |
2.5% |
| Congenital Cystic Kidney Disease |
2.5% |
| Device Malfunction |
2.5% |
| Device Misuse |
2.5% |
| Disease Progression |
2.5% |
| Drug Administration Error |
2.5% |
| Hypotension |
2.5% |
| Multi-organ Failure |
2.5% |
| Neonatal Disorder |
2.5% |
| Neonatal Hypoxia |
2.5% |
| Patent Ductus Arteriosus |
2.5% |
| Renal Disorder |
2.5% |
| Ventricular Fibrillation |
2.5% |
| White Blood Cell Count Decreased |
2.5% |
|
| Concomitant |
| Pulmonary Hypertension |
20.0% |
| Prophylaxis |
16.0% |
| Arrhythmia |
8.0% |
| Hypotension |
8.0% |
| Product Used For Unknown Indication |
8.0% |
| Sedation |
8.0% |
| Analgesic Therapy |
4.0% |
| Cardiac Disorder |
4.0% |
| Cardiac Failure High Output |
4.0% |
| Cardiac Output |
4.0% |
| Coronary Artery Bypass |
4.0% |
| Patent Ductus Arteriosus |
4.0% |
| Tardive Dyskinesia |
4.0% |
| Ventricular Assist Device Insertion |
4.0% |
|
| Renal Failure |
25.0% |
| Ill-defined Disorder |
12.5% |
| Post Procedural Haemorrhage |
12.5% |
| Pulmonary Hypertension |
12.5% |
| Pulmonary Interstitial Emphysema Syndrome |
12.5% |
| Respiratory Acidosis |
12.5% |
| Therapy Non-responder |
12.5% |
|
